TAIAN CITY, Shandong, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China (the "PRC"), today announced that on August 6, 2008, the PRC's State Food and Drug Administration (the "SFDA") granted China Biologic's production facility in Taian City renewal of its certification of compliance with Good Manufacturing Practices ("GMP") set by the SFDA.
In January 2008, the SFDA implemented stricter pharmaceutical GMP inspection standards designed to intensify supervision of drug producers and ensure drug quality. The new inspection standards include 259 articles, up from 225 articles in the previous standards, covering areas such as the sourcing of raw materials, manufacturing processes, self-inspection processes at each stage of production and transportation.
China Biologic's newly constructed facility with 700 tons of annual production capacity for plasma-based products was certified to be in compliance with the new standards. The renewed GMP Certification replaces the current GMP certification for the production facility, which was renewed in 2004. The GMP certification is valid for five years following the date of issuance.
"Our renewed GMP certification allows us to commence production in our new facility, which we believe will position us to become a leader in the production of plasma-based products in China," said Mr. Chao Ming Zhao, the Company's CEO. "We are currently one of only 32 biopharmaceutical companies in China to hold the GMP certification to manufacture plasma-based products. We plan to maintain our compliance with GMP standards and to continue supplying high quality products to our customers."
About Chinese Good Manufacturing Practices (GMP)
The certification of GMP is an effective measure for assuring the
quality, safety, and effective
|SOURCE China Biologic Products, Inc.|
Copyright©2008 PR Newswire.
All rights reserved